{"id":107759,"date":"2019-05-08T00:00:50","date_gmt":"2019-05-17T09:18:48","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/107759\/"},"modified":"2019-05-17T17:18:51","modified_gmt":"2019-05-17T09:18:51","slug":"0507856b31","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/107759\/","title":{"rendered":"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1"},"content":{"rendered":"
\n

1.\t\u201cA<\/strong><\/span>DP-TCR\u201d\u7597\u6cd5<\/strong><\/span>
<\/p>\n


<\/p>\n

\u201cADP-TCR\u201d\u7597\u6cd5\u662f\u7531Ad<\/span>aptimmune\u516c\u53f8\u5f00\u53d1\u7684\u4e00\u7cfb\u5217\u5de5\u7a0b\u5316TCR\u9776\u5411\u6297\u764c\u7597\u6cd5\uff0c\u4e3b\u8981\u5305\u62ec\uff1a<\/span><\/p>\n

1\uff09ADP-A2M10 T\u7ec6\u80de\u7597\u6cd5\uff0c\u8be5\u7597\u6cd5\u4e3b\u8981\u901a\u8fc7\u8bbe\u8ba1\u9776\u5411\u764c\u7ec6\u80de\u6297\u539fMAGE-A10\u7684\u8f6c\u57fa\u56e0T\u7ec6\u80de\uff0c\u7528\u4e8e\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u3001\u8180\u80f1\u764c\u3001\u9ed1\u8272\u7d20\u7624\u4ee5\u53ca\u5934\u9888\u764c\u3002<\/span><\/p>\n

2\uff09ADP-A2M4 T\u7ec6\u80de\u7597\u6cd5\uff0c\u4e3b\u8981\u9776\u5411\u764c\u7ec6\u80de\u6297\u539fMAGE-A4\uff0c\u4e3b\u8981\u6cbb\u7597\u5305\u62ec\u8180\u80f1\u764c\uff0c\u9ed1\u8272\u7d20\u7624\uff0c\u5934\u9888\u764c\u5728\u5185\u7684\u591a\u79cd\u5b9e\u4f53\u7624\u3002<\/span><\/p>\n

3\uff09ADP-A2AFP\uff0c\u9776\u5411\u80bf\u7624\u6297\u539f\u5206\u5b50\u4e3aAFP\uff0c\u4e3b\u8981\u7528\u4e8e\u6cbb\u7597\u809d\u764c\u3002\u76ee\u524d\u4e0a\u8ff0\u7597\u6cd5\u5747\u5904\u4e8e\u4e34\u5e8aI\u671f\u9636\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"

<\/span><\/p>\n

Adaptimmune \u516c\u53f8\u7684\u524d\u8eab\u662f1993\u5e74\u6210\u7acb\u4e8e\u725b\u6d25\u5927\u5b66\u7684\u201cTCR Technology\u201d\u516c\u53f8\u30021999\u5e74\u201cTCR Technology\u201d\u516c\u53f8\u53d8\u66f4\u4e3aAvidex\u516c\u53f8\u30022006\u5e74\uff0c\u88abMedigene\u516c\u53f8\u6536\u8d2d\uff0c\u800cAdaptimmune\u516c\u53f8\u5219\u4ece\u4e2d\u8131\u79bb\uff0c\u6210\u4e3a\u4e00\u5bb6\u72ec\u7acb\u7684\u751f\u7269\u5236\u836f\u4f01\u4e1a\u3002\u8fd1\u5341\u5e74\u6765\uff0c\u8be5\u516c\u53f8\u8fc5\u731b\u53d1\u5c55\uff0c\u5728\u53d6\u5f97GSK\u6218\u7565\u878d\u8d44\u7684\u540c\u65f6\uff0c\u591a\u9879\u6297\u764c\u7597\u6cd5\u8fdb\u5165\u4e34\u5e8a\u8bd5\u9a8c\u5e76\u53d6\u5f97\u4ee4\u4eba\u6ee1\u610f\u7684\u7ed3\u679c\u30022016\u5e74\uff0cAdaptimmune\u516c\u53f8\u5728\u7eb3\u65af\u8fbe\u514b\u4e0a\u5e02\uff0c\u540c\u65f6\u5176\u7a81\u7834\u6027\u7597\u6cd5\u201cNY-ESO\u201dT\u7ec6\u80de\u7597\u6cd5\u4e5f\u95ee\u4e16\u3002<\/span><\/p>\n


2.\tGam<\/strong><\/span>ma Delta (\u03b3\u03b4) T \u7ec6\u80de\u7597\u6cd5<\/strong><\/span><\/p>\n


<\/p>\n

Gamma Delta (\u03b3\u03b4) T \u7ec6\u80de\u7597\u6cd5<\/span>\u662f\u7531Adicet Bio\u516c\u53f8\u5f00\u53d1\u7684\u65b0\u578b\u6297\u764c\u7ec6\u80de\u7597\u6cd5\u3002\u76ee\u524d\u5de5\u7a0b\u5316\u7684Gamma Delta (\u03b3\u03b4) T\u7ec6\u80de\u4ea7\u54c1\u5df2\u5728\u8840\u6db2\u6076\u6027\u80bf\u7624\u7684\u6cbb\u7597\u4e2d\u663e\u793a\u51fa\u529f\u6548; \u7136\u800c\uff0c\u5c1a\u672a\u8bc1\u5b9e\u5728\u5b9e\u4f53\u7624\u4e2d\u5177\u6709\u76f8\u5f53\u7684\u7597\u6548\u3002 Adicet\u516c\u53f8\u6b63\u5728\u5f00\u53d1\u7684\u7ec6\u80de\u5e73\u53f0\u548c\u65b0\u578b\u9776\u5411\u65b9\u6cd5\uff0c\u65e8\u5728\u5229\u7528\u03b3\u03b4T\u7ec6\u80de\u7684\u80bf\u7624\u7279\u5f02\u6027\u514d\u75ab\uff0c\u53d1\u6325\u5176\u5728\u5b9e\u4f53\u80bf\u7624\u4e2d\u7684\u4f5c\u7528\u3002\u76ee\u524d\u8be5\u7597\u6cd5\u5904\u4e8e\u524d\u4e34\u5e8a\u8bd5\u9a8c\u9636\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

3.\t\u201c<\/strong><\/span>Anti-AFP CAR-T\u201d\u7ec6\u80de\u7597\u6cd5<\/strong><\/span><\/p>\n


<\/p>\n

AFP\uff08\u53c8<\/span>\u53eb\u7532\u80ce\u86cb\u767d\uff09<\/span>\u662f\u4e00\u79cd\u5206\u6ccc\u578b\u7684\u7cd6\u86cb\u767d\uff0c\u6b63\u5e38\u60c5\u51b5\u4e0b\uff0c\u8fd9\u79cd\u86cb\u767d\u4e3b\u8981\u6765\u81ea\u80da\u80ce\u7684\u809d\u7ec6\u80de\uff0c\u80ce\u513f\u51fa\u751f\u540e\u7ea6\u4e24\u5468\u7532\u80ce\u86cb\u767d\u4ece\u8840\u6db2\u4e2d\u6d88\u5931\uff0c\u56e0\u6b64\u6b63\u5e38\u6210\u5e74\u4eba\u8840\u6e05\u4e2d\u7532\u80ce\u86cb\u767d\u7684\u542b\u91cf\u5c1a\u4e0d\u523020\u5fae\u514b\/\u5347\u3002\u4f46\u5f53\u809d\u7ec6\u80de\u53d1\u751f\u764c\u53d8\u65f6\uff0c\u5374\u53c8\u6062\u590d\u4e86\u4ea7\u751f\u8fd9\u79cd\u86cb\u767d\u8d28\u7684\u529f\u80fd\uff0c\u800c\u4e14\u968f\u7740\u75c5\u60c5\u6076\u5316\u5b83\u5728\u8840\u6e05\u4e2d\u7684\u542b\u91cf\u4f1a\u6025\u5267\u589e\u52a0\uff0c\u7532\u80ce\u86cb\u767d\u5c31\u6210\u4e86\u8bca\u65ad\u539f\u53d1\u6027\u809d\u764c\u7684\u4e00\u4e2a\u7279\u5f02\u6027\u4e34\u5e8a\u6307\u6807\u3002\u7531\u4e8e\u6b63\u5e38\u7ec4\u7ec7\u57fa\u672c\u4e0d\u8868\u8fbeAFP\uff0c\u56e0\u6b64\u5f53AFP\u5728\u80de\u5185\u5207\u5272\u540e\u88abMHC\u5448\u9012\u5230\u7ec6\u80de\u819c\u8868\u9762\u65f6\u5219\u53ef\u4ee5\u4f5c\u4e3aCAR-T\u6cbb\u7597\u539f\u53d1\u6027\u809d\u7ec6\u80de\u764c\u7684\u9776\u6807\u3002\u76ee\u524d\u8be5\u4ea7\u54c1\u7531\u9890\u6602\u751f\u7269\u79d1\u6280\uff08\u5317\u4eac\uff09\u6709\u9650\u516c\u53f8\u5f00\u53d1\uff0c\u5904\u4e8e\u4e34\u5e8a\u7814\u7a76\u9636\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/span><\/p>\n


<\/p>\n

\u6b64\u5916\uff0c\u8be5\u516c\u53f8\u8fd8\u5728\u524d\u8005\u7684\u57fa\u7840\u4e0a\u5f15\u5165\u4e86ARTEMIS\u5e73\u53f0\u3002ARTEMIS\u5e73\u53f0\u662f\u4eceT\u7ec6\u80de\u7684\u81ea\u7136\u751f\u7269\u5b66\u7279\u6027\u800c\u8bbe\u8ba1\u6765\u6297\u764c\u7684\u521b\u65b0\u578b\u4e13\u6709\u6280\u672f\u5e73\u53f0\uff0c\u5b83\u5177\u6709\u5927\u5927\u964d\u4f4e\u6216\u6d88\u9664\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\uff08CRS\uff09\u548c\u5176\u4ed6\u5a01\u80c1\u60a3\u8005\u751f\u547d\u7684\u7ec6\u80de\u56e0\u5b50\u76f8\u5173\u6bd2\u6027\u7684\u6f5c\u529b\u3002ARTEMIS\u5e73\u53f0\u901a\u8fc7\u5c06T\u7ec6\u80de\u6fc0\u6d3b\u4e0e\u7ec6\u80de\u5185\u5728\u8c03\u8282\u673a\u5236\u8026\u5408\u8bbe\u8ba1\u4e86ARTEMIS\u53d7\u4f53\uff0c\u4ee5\u63d0\u4f9b\u66f4\u5b89\u5168\u548c\u66f4\u6709\u6548\u7684T\u7ec6\u80de\u6cbb\u7597\uff0c\u5b83\u6709\u4e24\u4e2a\u6838\u5fc3\u529f\u80fd\u7ec4\u4ef6\uff1a\u57fa\u4e8e\u6297\u4f53\u7684\u6297\u539f\u7ed3\u5408\u57df\u548c\u6548\u5e94\u5668\u57df\u3002ARTEMIS\u53d7\u4f53\u7684\u8bbe\u8ba1\u5141\u8bb8\u5b83\u91c7\u7528\u5185\u6e90\u6027TCR\u901a\u5e38\u91c7\u7528\u7684\u6fc0\u6d3b\u548c\u8c03\u8282\u9014\u5f84\u3002\u5e76\u4e14\u7531\u4e8e\u6ca1\u6709\u5c06\u7ec6\u80de\u5185\u4fe1\u53f7\u8f6c\u5bfc\u57df\u76f4\u63a5\u8026\u5408\u5230\u5171\u523a\u6fc0\u57df\uff0c\u56e0\u6b64ARTEMIS\u53ef\u4ee5\u907f\u514dT\u7ec6\u80de\u8fc7\u5ea6\u6fc0\u6d3b\uff0c\u4ece\u800c\u5927\u5927\u964d\u4f4eCRS\u7b49\u7531\u4e8e\u7ec6\u80de\u56e0\u5b50\u8fc7\u91cf\u91ca\u653e\u5bfc\u81f4\u7684\u76f8\u5173\u6bd2\u6027\u3002\u76ee\u524d\u8be5\u7597\u6cd5\u5904\u4e8e\u524d\u4e34\u5e8a\u7814\u7a76\u9636\u6bb5\u3002\u53e6\u5916\uff0c\u8fd8\u5728\u524d\u8005\u7684\u57fa\u7840\u4e0a\u52a0\u5165\u4e86PD-1\u7684\u4e00\u81f4\u6027\u6297\u4f53\u7247\u6bb5\u8fdb\u884c\u8054\u5408\u6cbb\u7597\u3002\u8be5\u7597\u6cd5\u76ee\u524d\u4e5f\u5904\u4e8e\u524d\u4e34\u5e8a\u7814\u7a76\u9636\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

4.\t\u5e26\u6709\u5206\u5b50\u5f00\u5173\u7684\u201cCAR-T\u201d\u7ec6\u80de\u7597\u6cd5<\/strong><\/span><\/p>\n


<\/p>\n

Bellicum Pharmaceuticals\u516c\u53f8\u5f00\u53d1\u4e86\u4e00\u6b3e\u5e26\u6709\u201ciMC\u201d\u5206\u5b50\u5f00\u5173\u7684CAR-T\u7597\u6cd5\uff0c\u8be5\u7597\u6cd5\u80fd\u591f\u51c6\u786e\u8bc6\u522b\u8868\u8fbe\u524d\u5217\u817a\u6297\u539f\uff08PSCA\uff09\u7684\u5b9e\u4f53\u7624\u7ec6\u80de\uff0c\u5e76\u8fdb\u884c\u9776\u5411\u6740\u4f24\u3002\u76ee\u524d\u8be5\u7597\u6cd5\u6b63\u5904\u4e8e\u4e34\u5e8a\u5f00\u53d1\u7684\u5173\u952e\u9636\u6bb5\u3002<\/span><\/p>\n

 \"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"

<\/span><\/p>\n

5.\t<\/span>An<\/span><\/span><\/strong>ti-CD19\uff0cAnti-CD22 <\/span><\/strong>CAR-T\u7597\u6cd5<\/span><\/strong><\/p>\n


<\/p>\n

CD19\u662f\u4e00\u79cd<\/span>\u7ec6\u80de\u8868\u9762\u5206\u5b50\uff0c\u662fB\u7ec6\u80de\u589e\u6b96\u3001\u5206\u5316\u3001\u6d3b\u5316\u53ca\u6297\u4f53\u4ea7\u751f\u6709\u5173\u7684\u91cd\u8981\u819c\u6297\u539f\u3002CD19\u5206\u5e03\u4e8e\u5168\u4f53B\u7ec6\u80de\u3001\u6bdb\u7ec6\u80de\u767d\u8840\u75c5\u7ec6\u80de\u7b49\u6076\u6027B\u7ec6\u80de\u3001\u6ee4\u6ce1\u6811\u72b6\u7ec6\u80de\u4e0a\uff0c\u56e0\u6b64\u662f\u8bca\u65adB\u7ec6\u80de\u7cfb\u80bf\u7624\uff08\u767d\u8840\u75c5\u3001\u6dcb\u5df4\u7624\uff09\u548c\u9274\u5b9aB\u7ec6\u80de\u6700\u597d\u7684\u6807\u8bb0\u3002CD22\u662f\u5c5e\u4e8eSIGLEC\u51dd\u96c6\u7d20\u5bb6\u65cf\u7684\u5206\u5b50\u3002\u5b83\u4e3b\u8981\u5b58\u5728\u4e8e\u6210\u719fB\u7ec6\u80de\u7684\u8868\u9762\u3002\u4e00\u822c\u6765\u8bf4\uff0cCD22\u662f\u4e00\u79cd\u8c03\u8282\u5206\u5b50\uff0c\u53ef\u4ee5\u9632\u6b62\u514d\u75ab\u7cfb\u7edf\u7684\u8fc7\u5ea6\u6d3b\u5316\u548c\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u7684\u53d1\u5c55\u3002\u7136\u800c\uff0c\u6700\u8fd1\u7814\u7a76\u53d1\u73b0CD22\u662f\u9664\u4e86CD19\u4e4b\u5916\u7684\u53e6\u5916\u4e00\u4e2a\u53ef\u4ee5\u6307\u5f81B\u7ec6\u80de\u6076\u6027\u80bf\u7624\u7684\u5206\u5b50\u6807\u8bb0\u3002Juno Therapeutics\u516c\u53f8\u4e13\u6ce8\u4e8eCAR-T\u4ee5\u53caTCR-T\u7684\u6297\u764c\u7ec6\u80de\u7597\u6cd5\u7684\u5f00\u53d1\u3002\u5176\u5728\u7814\u4ea7\u54c1\u5305\u62ecCD19\u7279\u5f02\u6027CAR-T\u7ec6\u80de\u6cbb\u7597\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff0cCD22\u7279\u5f02\u6027CAR-T\u7ec6\u80de\u6cbb\u7597\u513f\u7ae5\u6025\u6027\u6dcb\u5df4\u7624\u3001TCR\u7279\u5f02\u6027T\u7ec6\u80de\u6cbb\u7597\u6025\u6027\u9aa8\u9ad3\u7624\u3001\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7b49\u7b49\u3002\u76ee\u524d\u5927\u591a\u6570\u7597\u6cd5\u4ecd\u5904\u4e8e\u4e34\u5e8aI\u671f\u9636\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/span><\/p>\n


<\/p>\n

\u5728\u6211\u56fd\uff0c\u5409\u51ef\u57fa\u56e0\u5df2\u4e0e\u957f\u6d77\u533b\u9662\u8840\u6db2\u79d1\u5408\u4f5c\u5f00\u5c55CD19-CART\u6cbb\u7597\u590d\u53d1\u96be\u6cbbB-ALL, CLL\u548cB-NHL\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7814\u7a76\uff0c CD19-CART\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\u663e\u793a\uff0c\u5df2\u7ecf\u6cbb\u7597\u768414\u4f8b\u60a3\u8005\u90fd\u5f97\u5230\u4e86\u4e0d\u540c\u7684\u63a7\u5236\uff0c\u5176\u4e2d12\u4f8b\u60a3\u8005\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\uff0c2\u4f8b\u75c7\u72b6\u7a33\u5b9a\uff08SD\uff09\uff0c\u81f3\u4eca\u65e0\u4e00\u4f8b\u75c5\u4eba\u51fa\u73b0\u4e25\u91cd\u5e76\u53d1\u75c7\u800c\u6b7b\u4ea1\u3002<\/span><\/p>\n

 <\/span>\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/span><\/span><\/p>\n


<\/p>\n

\u6b64\u5916\uff0c\u516c\u53f8\u5728\u7814\u7684CD22-CART \u4ea7\u54c1\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u96be\u6cbbB-ALL, CLL \u548cB-NHL\uff0c\u4ee5\u53caCD123-CART \u4ea7\u54c1\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u96be\u6cbb\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5AML\u76ee\u524d\u5df2\u7ecf\u8fdb\u5165\u4e34\u5e8a\u8bd5\u9a8c\u9636\u6bb5\u3002BCMA-CART \u7814\u7a76\u590d\u53d1\u96be\u6cbb\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u76ee\u524d\u5904\u4e8e\u4e34\u5e8a\u524d\u7814\u7a76\u9636\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

6.\t\u9488\u5bf9\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u5f15\u53d1\u764c\u75c7\u7684TCR\u7ec6\u80de\u7597\u6cd5<\/span><\/strong><\/p>\n


<\/p>\n

\u5728\u4e9a\u6d32\uff0c\u6bcf\u5e74\u8d85\u8fc720\uff05\u7684\u65b0\u764c\u75c7\u75c5\u4f8b\u53ef\u5f52\u56e0\u4e8e\u6162\u6027\u611f\u67d3\u3002 \u7279\u522b\u662f\uff0c\u7edd\u5927\u591a\u6570\u809d\u7ec6\u80de\u764c\u662f\u7531\u4e8e\u5728\u4e9a\u6d32\u6d41\u884c\u7684\u4e59\u578b\u809d\u708e\u75c5\u6bd2\uff08HBV\uff09\u7684\u6162\u6027\u611f\u67d3\u5f15\u8d77\u7684\u3002<\/span><\/p>\n

 \"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/span><\/p>\n


<\/p>\n

\u6162\u6027\u75c5\u6bd2\u611f\u67d3\u901a\u8fc7\u5f15\u8d77\u91cd\u590d\u7ec4\u7ec7\u635f\u4f24\uff0c\u708e\u75c7\u548c\u75c5\u6bd2\u57fa\u56e0\u6574\u5408\u5230\u5bbf\u4e3b\u57fa\u56e0\u7ec4\u4e2d\u800c\u4f7f\u4eba\u6613\u60a3\u764c\u75c7\u3002\u6574\u5408\u7684\u75c5\u6bd2\u57fa\u56e0\u53ef\u4ee5\u901a\u8fc7\u5bbf\u4e3b\u673a\u5236\u8868\u8fbe\uff0c\u4ee5\u4ea7\u751f\u75c5\u6bd2\u884d\u751f\u7684\u86cb\u767d\u8d28\u7247\u6bb5\uff0c\u7136\u540e\u5c06\u5176\u964d\u89e3\u6210\u75c5\u6bd2\u80bd\u5e76\u4e0eMHC I\u7c7b\u7ec4\u88c5\u4ee5\u5448\u9012\u5230\u7ec6\u80de\u8868\u9762\u4e0a\u3002\u56e0\u6b64\uff0c\u8fd9\u4e9b\u764c\u7ec6\u80de\u88ab\u7528\u4f5c\u80bf\u7624\u6297\u539f\u7684\u75c5\u6bd2\u80bd\u7279\u5f02\u6027\u6807\u8bb0\u3002\u901a\u8fc7\u4e13\u6709\u7684TCR\u5e73\u53f0\uff0c\u4f7f\u7528\u9ad8\u4eb2\u548c\u529b\u6297\u75c5\u6bd2TCR\u91cd\u65b0\u7f16\u8f91\u60a3\u8005\u7684T\u7ec6\u80de\uff0c\u8be5TCR\u8bc6\u522b\u80bf\u7624\u7279\u5f02\u6027\u75c5\u6bd2\u80bd\uff0c\u5bfc\u81f4\u7ec6\u80de\u6eb6\u89e3\u5206\u5b50\u7684\u91ca\u653e\u548c\u764c\u7ec6\u80de\u7684\u6eb6\u89e3\u3002Lion TCR\u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u6280\u672f\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u5f00\u53d1\u9488\u5bf9\u5a01\u80c1\u751f\u547d\u7684\u75c5\u6bd2\u611f\u67d3\u548c\u4e9a\u6d32\u76f8\u5173\u7684\u75c5\u6bd2\u76f8\u5173\u764c\u75c7\u7684T\u7ec6\u80de\u53d7\u4f53\uff08TCR\uff09-T\u7ec6\u80de\u7597\u6cd5\u3002\u76ee\u524d\u8be5\u516c\u53f8\u5728\u7814\u7684\u4ea7\u54c1\u4e3b\u8981\u5305\u62ec\uff1a1\u3001\u6cbb\u7597\u809d\u810f\u79fb\u690d\u540e\u56e0\u611f\u67d3\u800c\u51fa\u73b0\u7684\u809d\u810f\u764c\u53d8\uff0c\u8fd9\u7c7b\u7597\u6cd5\u76ee\u524d\u5904\u4e8e\u4e34\u5e8aI\u671f\u9636\u6bb5\uff1b2\u3001\u6cbb\u7597\u56e0EBV\u611f\u67d3\u5f15\u53d1\u7684\u764c\u75c7\uff0c\u76ee\u524d\u8be5\u7597\u6cd5\u5904\u4e8e\u524d\u4e34\u5e8a\u7814\u7a76\u9636\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

7.\tYescarta<\/span><\/strong><\/p>\n


<\/p>\n

Yescarta\u662f\u5168\u7403\u9996\u4e2a\u83b7\u6279\u6cbb\u7597\u7279\u5b9a\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u7684 CAR-T\u7ec6\u80de\u836f\u7269\uff0c 2017\u5e7410\u670818\u65e5\u83b7\u5f97\u7f8e\u56fdFDA\u6279\u51c6\u4e0a\u5e02\uff0c2018\u5e748\u670827\u65e5\u83b7\u5f97EMA\u6279\u51c6\u5728\u6b27\u6d32\u5e02\u573a\u4e0a\u5e02\u3002Kite Pharma\u516c\u5e03\u7684ZUMA-1\u4e24\u5e74\u968f\u8bbf\u6570\u636e\u663e\u793a\uff0c101\u540d\u96be\u6cbb\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u63a5\u53d7Yescarta\u6cbb\u7597\uff0c\u6700\u4f73\u603b\u7f13\u89e3\u7387\u4e3a83%\uff0c\u5b8c\u5168\u7f13\u89e3\u7387\u8fbe\u5230\u4e8658%\uff1b\u4e2d\u4f4d\u968f\u8bbf15.1\u4e2a\u6708\uff0c\u670942%\u7684\u53d7\u8bd5\u8005\u7ef4\u6301\u7f13\u89e3\uff0c\u5176\u4e2d40%\u7ef4\u6301\u5b8c\u5168\u7f13\u89e3\uff0c\u4e2d\u4f4d\u6301\u7eed\u65f6\u95f4\u8fbe\u523011.1\u4e2a\u6708\uff1b\u4e2d\u4f4d\u968f\u8bbf 27.1\u4e2a\u6708, \u4ecd\u6709 39%\u7684\u53d7\u8bd5\u8005\u7ef4\u6301\u7f13\u89e3\uff0c\u5176\u4e2d37%\u7ef4\u6301\u5b8c\u5168\u7f13\u89e3\u30022017\u5e741\u670811\u65e5\uff0c\u590d\u661f\u533b\u836f\u5ba3\u5e03\uff0c\u901a\u8fc7\u65d7\u4e0b\u5168\u8d44\u5b50\u516c\u53f8\u6210\u7acb\u4e2d\u5916\u5408\u8425\u4f01\u4e1a\uff0c\u62df\u5728\u4e2d\u56fd\u5f15\u8fdbKitePharma\u516c\u53f8\u7684CAR-T\u6cbb\u7597\u4ea7\u54c1KTE-C19\uff0c\u4e3a\u6dcb\u5df4\u764c\u60a3\u8005\u5e26\u6765\u5168\u7403\u9886\u5148\u7684\u6cbb\u7597\u624b\u6bb5\u3002<\/span><\/p>\n


<\/p>\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/p>\n


<\/p>\n

\u590d\u661f\u51ef\u7279\u5728\u7814\u4ea7\u54c1FKC876\uff08\u7f8e\u56fd\u5546\u54c1\u540d Yescarta\uff09\u5df2\u83b7\u5f97\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u9881\u53d1\u7684\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\uff08IND\uff09\u6279\u4ef6\uff0c\u5c06\u88ab\u5f00\u53d1\u7528\u4e8e\u6cbb\u7597\u4e8c\u7ebf\u6216\u4ee5\u4e0a\u7cfb\u7edf\u6027\u6cbb\u7597\u540e\u590d\u53d1\u6216\u96be\u6cbb\u6027\u5927 B\u7ec6\u80de\u6dcb\u5df4\u7624\uff0c\u5305\u62ec\uff1a\u5f25\u6f2b\u6027\u5927 B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08 DLBCL\uff09\u975e\u7279\u6307\u578b\u3001\u539f\u53d1\u6027\u7eb5\u9694 B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08 PMBCL\uff09\u3001\u9ad8\u7ea7\u522b B\u7ec6\u80de\u6dcb\u5df4\u7624\u548c\u6ee4\u6ce1\u7624\u8f6c\u5316\u7684 DLBCL\u3002<\/span><\/span><\/p>\n


<\/p>\n

8.\tAnti-EGFR CAR-T\u7597\u6cd5<\/span><\/strong><\/p>\n


<\/p>\n

EGFR\uff08Epidermal Growth Factor Receptor\uff09\u662f\u4e0a\u76ae\u751f\u957f\u56e0\u5b50\uff08EGF\uff09\u7ec6\u80de\u589e\u6b96\u548c\u4fe1\u53f7\u4f20\u5bfc\u7684\u53d7\u4f53\u3002EGFR\u4f4d\u4e8e\u7ec6\u80de\u819c\u8868\u9762\uff0c\u9760\u4e0e\u914d\u4f53\u7ed3\u5408\u6765\u6fc0\u6d3b\uff0c\u5305\u62ecEGF\u548cTGF\u03b1\uff08transforming growth factor \u03b1\uff09\u3002\u6fc0\u6d3b\u540e\uff0cEGFR\u7531\u5355\u4f53\u8f6c\u5316\u4e3a\u4e8c\u805a\u4f53\uff0c\u8fdb\u800c\u6fc0\u6d3b\u5b83\u4f4d\u4e8e\u7ec6\u80de\u5185\u7684\u6fc0\u9176\u901a\u8def\u3002\u81ea\u78f7\u9178\u5316\u53ef\u4ee5\u5f15\u5bfc\u4e0b\u6e38\u7684\u78f7\u9178\u5316\uff0c\u5305\u62ecMAPK\uff0cAkt\u548cJNK\u901a\u8def, \u8bf1\u5bfc\u7ec6\u80de\u589e\u6b96\u3002\u6b64\u524d\u7814\u7a76\u8868\u660e\u5728\u8bb8\u591a\u5b9e\u4f53\u80bf\u7624\u4e2d\u5b58\u5728EGFR\u7684\u9ad8\u8868\u8fbe\u6216\u5f02\u5e38\u8868\u8fbe\u3002EGFR\u4e0e\u80bf\u7624\u7ec6\u80de\u7684\u589e\u6b96\u3001\u8840\u7ba1\u751f\u6210\u3001\u80bf\u7624\u4fb5\u88ad\u3001\u8f6c\u79fb\u53ca\u7ec6\u80de\u51cb\u4ea1\u7684\u6291\u5236\u6709\u5173\u3002\u6b64\u5916\uff0c\u7814\u7a76\u53d1\u73b0EGFR\u53ef\u4ee5\u901a\u8fc7Ang-1\u53caVEGF\u7b49\u56e0\u5b50\u6c34\u5e73\u7684\u8c03\u8282\u800c\u5f71\u54cd\u80bf\u7624\u8840\u7ba1\u751f\u6210\u3002\u56e0\u6b64\uff0cEGFR\u88ab\u770b\u505a\u662f\u80bf\u7624\u9776\u5411\u6cbb\u7597\u7684\u5173\u952e\u4f4d\u70b9\u3002\u897f\u6bd4\u66fc\u751f\u7269\u79d1\u6280\uff082014\u5e74\u5728\u7f8e\u56fd\u7eb3\u65af\u8fbe\u514b\u6302\u724c\u4e0a\u5e02\uff0c\u6210\u4e3a\u7b2c\u4e00\u4e2a\u5728\u7f8e\u56fd\u7eb3\u65af\u8fbe\u514b\u4e0a\u5e02\u7684\u4e2d\u56fd\u7ec6\u80de\u751f\u7269\u533b\u836f\u79d1\u6280\u516c\u53f8\uff09\u81f4\u529b\u4e8eanti-EGFR CAR-T\u7597\u6cd5\u7684\u5f00\u53d1\u4e0e\u4e34\u5e8a\u5e94\u7528\u3002\u901a\u8fc7\u4e0e\u89e3\u653e\u519b301\u533b\u9662\u5408\u4f5c\uff0c2015\u5e742\u6708\u4ee51200\u4e07\u6536\u8d2d\u4e86\u89e3\u653e\u519b\u603b\u533b\u9662\uff08301\u533b\u9662\uff09\u76844\u9879CAR-T\u4ea7\u54c1\uff0c\u5e76\u4fdd\u7559\u540e\u7eed\u4ea7\u54c1\u7684\u4f18\u5148\u6536\u8d2d\u6743\u3002\u897f\u6bd4\u66fc\u5728CAR-T\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e3b\u8981\u96c6\u4e2d\u5728\u4e34\u5e8a\u2161\u671f\uff0c\u4ece\u76ee\u524d\u516c\u53f8\u516c\u5e03\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u6765\u770b\uff0c\u521d\u6b65\u663e\u793a\u8fd9\u4e9b\u4ea7\u54c1\u76f8\u5bf9\u5b89\u5168\u3001\u53ef\u884c\u548c\u6709\u6548\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u5176\u9488\u5bf9\u5b9e\u4f53\u7624EGFR\u9776\u70b9\u7684CAR-T\u7597\u6cd5\u201cCBM-EGFR.1\u201d\u7684\u2160\u671f\u4e34\u5e8a\u6570\u636e\uff0c\u5728\u591a\u79cd\u7c7b\u578b\u5b9e\u4f53\u7624\u4e0a\u53d6\u5f97\u4e86\u5e94\u7b54\uff0c\u7814\u53d1\u8fdb\u5ea6\u5904\u4e8e\u56fd\u9645\u9886\u5148\u3002<\/span><\/span><\/p>\n


<\/p>\n

9.\tAnti-GPC3 CAR-T\u7ec6\u80de\u7597\u6cd5<\/span><\/strong><\/p>\n


<\/p>\n

GPC3(Glypican 3)\u662f\u7531GPC3\u57fa\u56e0\u7f16\u7801\u7684\u7ec6\u80de\u8868\u9762\u86cb\u767d\u3002\u6b64\u524d\u7814\u7a76\u53d1\u73b0\uff0cGPC3\u662f\u6cbb\u7597\u809d\u764c\u548c\u5176\u4ed6\u764c\u75c7\u7684\u6f5c\u5728\u6cbb\u7597\u9776\u70b9\u3002\u76ee\u524d\u5df2\u7ecf\u5f00\u53d1\u4e86\u51e0\u79cd\u6cbb\u7597\u6027\u6297GPC3\u6297\u4f53\u3002\u53e6\u4e00\u65b9\u9762\uff0c\u79d1\u6d4e\u751f\u7269\u5219\u4e13\u6ce8\u4e8e\u5f00\u53d1\u4ee5GPC3\u4e3a\u9776\u70b9\u7684CAR-T\u7ec6\u80de\u7597\u6cd5\u7684\u5f00\u53d1\uff0c\u5e76\u5f00\u5c55\u4e86\u5168\u7403\u9996\u4e2a\u9488\u5bf9\u809d\u7ec6\u80de\u764c\u7684CAR-GPC3 T\u4e34\u5e8a\u8bd5\u9a8c\u3002\u6b64\u5916\uff0c\u79d1\u6280\u751f\u7269\u8fd8\u5f00\u5c55\u4e86\u9488\u5bf9\u80f6\u6bcd\u7ec6\u80de\u7624(GBM)\u7684EGFR\/EGFRvIII\u53cc\u9776\u70b9\u7684CAR-T\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u9488\u5bf9\u80c3\u764c\u3001\u80f0\u817a\u764c\u7684Claudin18.2\u9776\u70b9\u6cbb\u7597\u7684CAR-T\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4ee5\u53ca\u5e94\u7528\u4eba\u6e90\u5316CD19 CAR-T\u6cbb\u7597\u767d\u8840\u75c5\u53ca\u6dcb\u5df4\u7624\u4e34\u5e8a\u7814\u7a76\u3002<\/span> <\/span><\/span><\/p>\n


<\/p>\n

10.\tAnti-BCMA CAR-T\u7597\u6cd5<\/span><\/strong><\/p>\n


<\/p>\n

BCMA\uff08B-cell maturation antigen\uff09\uff0c\u4e5f\u79f0\u4e3a\u80bf\u7624\u574f\u6b7b\u56e0\u5b50\u53d7\u4f53\u8d85\u5bb6\u65cf\u6210\u545817\uff08TNFRSF17\uff09\uff0c\u662f\u7531TNFRSF17\u57fa\u56e0\u7f16\u7801\u7684\u86cb\u767d\u8d28\u3002\u8be5\u53d7\u4f53\u662fTNF\u53d7\u4f53\u8d85\u5bb6\u65cf\u7684\u6210\u5458\uff0c\u4f18\u5148\u5728\u6210\u719fB\u6dcb\u5df4\u7ec6\u80de\u4e2d\u8868\u8fbe\uff0c\u5e76\u4e14\u53ef\u80fd\u5bf9B\u7ec6\u80de\u53d1\u80b2\u548c\u81ea\u8eab\u514d\u75ab\u5e94\u7b54\u5f88\u91cd\u8981\u3002\u5df2\u663e\u793a\u8be5\u53d7\u4f53\u7279\u5f02\u6027\u7ed3\u5408\u80bf\u7624\u574f\u6b7b\u56e0\u5b50\uff08\u914d\u4f53\uff09\u8d85\u5bb6\u65cf\u6210\u545813b\uff08TNFSF13B \/ TALL-1 \/ BAFF\uff09\uff0c\u5e76\u5bfc\u81f4NF-\u03baB\u548cMAPK8 \/ JNK\u6d3b\u5316\u3002\u8be5\u53d7\u4f53\u8fd8\u4e0e\u5404\u79cdTRAF\u5bb6\u65cf\u6210\u5458\u7ed3\u5408\uff0c\u56e0\u6b64\u53ef\u4ee5\u8f6c\u5bfc\u7ec6\u80de\u5b58\u6d3b\u548c\u589e\u6b96\u7684\u4fe1\u53f7\u3002\u6b64\u524d\u7814\u7a76\u63ed\u793a\uff0cTNFRSF17\u4e0e\u767d\u8840\u75c5\uff0c\u6dcb\u5df4\u7624\u548c\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u6709\u5173\u3002LCAR-B38M\u662f\u5357\u4eac\u4f20\u5947\u7814\u53d1\u7684\u4e00\u6b3e\u9776\u5411BCMA\u7684CAR-T\u7597\u6cd5\u3002\u6570\u636e\u663e\u793a\uff0c\u5728\u4e00\u987935\u4f8b\u590d\u53d1\u6027\u6216\u8010\u836f\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u53c2\u4e0e\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\uff0c\u8be5\u7597\u6cd5\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\u8fbe\u5230100%\u3002\u5728\u6700\u65e9\u63a5\u53d7\u6cbb\u7597\u768419\u4f8b\u60a3\u8005\u4e2d\uff0c\u5357\u4eac\u4f20\u5947\u5bf9\u5176\u89c2\u5bdf\u968f\u8bbf4-14\u4e2a\u6708\u4ee5\u4e0a\u3002\u5176\u4e2d14\u540d\u60a3\u8005\u6301\u7eed\u8fbe\u5230\u4e25\u683c\u5b8c\u5168\u53cd\u5e94\u8bca\u65ad\u6807\u51c6\uff0c5\u4f4d\u51fa\u73b0\u90e8\u5206\u7f13\u89e3\u3002\u9664\u4e86\u4e0a\u8ff0\u516c\u53f8\u4e4b\u5916\uff0c\u8fd8\u6709\u8bb8\u591a\u516c\u53f8\u4e5f\u81f4\u529b\u4e8e\u6297\u764c\u7ec6\u80de\u7597\u6cd5\u7684\u7814\u7a76\u3001\u5f00\u53d1\u4ee5\u53ca\u4e34\u5e8a\u5e94\u7528\uff0c\u4f8b\u5982BioNTech\uff0cBluebird bio\uff0c Medica\uff0cCRISPR Therapeutics\uff0cEditas Medicine\uff0cEureka Therapeutics\uff0cGadeta\uff0cGlaxoSmithKline\uff0cImmatics\uff0cImmunoular Therapeutics\uff0cIntellia Therapeutics\uff0cKite Pharma\uff0cMedigene\uff0cNeon Therapeutics\uff0cRegeneron Pharmaceuticals\uff0cSangamo Therapeutics\uff0cTactiva Therapeutics\uff0cTakara Bio\uff0cTC BioPharm\uff0cTCR2 Therapeutics\uff0cTmunity Therapeutics\uff0cUniversal s\uff0cZelluna Immunotherapy\uff0cZIOPHARM Oncology\u7b49\u7b49\uff0c\u6709\u5174\u8da3\u7684\u8bfb\u8005\u4e0d\u59a8\u81ea\u884c\u67e5\u9605\u3002<\/span><\/span><\/p>\n


<\/p>\n

BCMA\uff08B-cell maturation antigen\uff09\uff0c\u4e5f\u79f0\u4e3a\u80bf\u7624\u574f\u6b7b\u56e0\u5b50\u53d7\u4f53\u8d85\u5bb6\u65cf\u6210\u545817\uff08TNFRSF17\uff09\uff0c\u662f\u7531TNFRSF17\u57fa\u56e0\u7f16\u7801\u7684\u86cb\u767d\u8d28\u3002\u8be5\u53d7\u4f53\u662fTNF\u53d7\u4f53\u8d85\u5bb6\u65cf\u7684\u6210\u5458\uff0c\u4f18\u5148\u5728\u6210\u719fB\u6dcb\u5df4\u7ec6\u80de\u4e2d\u8868\u8fbe\uff0c\u5e76\u4e14\u53ef\u80fd\u5bf9B\u7ec6\u80de\u53d1\u80b2\u548c\u81ea\u8eab\u514d\u75ab\u5e94\u7b54\u5f88\u91cd\u8981\u3002\u5df2\u663e\u793a\u8be5\u53d7\u4f53\u7279\u5f02\u6027\u7ed3\u5408\u80bf\u7624\u574f\u6b7b\u56e0\u5b50\uff08\u914d\u4f53\uff09\u8d85\u5bb6\u65cf\u6210\u545813b\uff08TNFSF13B \/ TALL-1 \/ BAFF\uff09\uff0c\u5e76\u5bfc\u81f4NF-\u03baB\u548cMAPK8 \/ JNK\u6d3b\u5316\u3002\u8be5\u53d7\u4f53\u8fd8\u4e0e\u5404\u79cdTRAF\u5bb6\u65cf\u6210\u5458\u7ed3\u5408\uff0c\u56e0\u6b64\u53ef\u4ee5\u8f6c\u5bfc\u7ec6\u80de\u5b58\u6d3b\u548c\u589e\u6b96\u7684\u4fe1\u53f7\u3002\u6b64\u524d\u7814\u7a76\u63ed\u793a\uff0cTNFRSF17\u4e0e\u767d\u8840\u75c5\uff0c\u6dcb\u5df4\u7624\u548c\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u6709\u5173\u3002LCAR-B38M\u662f\u5357\u4eac\u4f20\u5947\u7814\u53d1\u7684\u4e00\u6b3e\u9776\u5411BCMA\u7684CAR-T\u7597\u6cd5\u3002\u6570\u636e\u663e\u793a\uff0c\u5728\u4e00\u987935\u4f8b\u590d\u53d1\u6027\u6216\u8010\u836f\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u53c2\u4e0e\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\uff0c\u8be5\u7597\u6cd5\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\u8fbe\u5230100%\u3002\u5728\u6700\u65e9\u63a5\u53d7\u6cbb\u7597\u768419\u4f8b\u60a3\u8005\u4e2d\uff0c\u5357\u4eac\u4f20\u5947\u5bf9\u5176\u89c2\u5bdf\u968f\u8bbf4-14\u4e2a\u6708\u4ee5\u4e0a\u3002\u5176\u4e2d14\u540d\u60a3\u8005\u6301\u7eed\u8fbe\u5230\u4e25\u683c\u5b8c\u5168\u53cd\u5e94\u8bca\u65ad\u6807\u51c6\uff0c5\u4f4d\u51fa\u73b0\u90e8\u5206\u7f13\u89e3\u3002\u9664\u4e86\u4e0a\u8ff0\u516c\u53f8\u4e4b\u5916\uff0c\u8fd8\u6709\u8bb8\u591a\u516c\u53f8\u4e5f\u81f4\u529b\u4e8e\u6297\u764c\u7ec6\u80de\u7597\u6cd5\u7684\u7814\u7a76\u3001\u5f00\u53d1\u4ee5\u53ca\u4e34\u5e8a\u5e94\u7528\uff0c\u4f8b\u5982BioNTech\uff0cBluebird bio\uff0c Medica\uff0cCRISPR Therapeutics\uff0cEditas Medicine\uff0cEureka Therapeutics\uff0cGadeta\uff0cGlaxoSmithKline\uff0cImmatics\uff0cImmunoular Therapeutics\uff0cIntellia Therapeutics\uff0cKite Pharma\uff0cMedigene\uff0cNeon Therapeutics\uff0cRegeneron Pharmaceuticals\uff0cSangamo Therapeutics\uff0cTactiva Therapeutics\uff0cTakara Bio\uff0cTC BioPharm\uff0cTCR2 Therapeutics\uff0cTmunity Therapeutics\uff0cUniversal s\uff0cZelluna Immunotherapy\uff0cZIOPHARM Oncology\u7b49\u7b49\uff0c\u6709\u5174\u8da3\u7684\u8bfb\u8005\u4e0d\u59a8\u81ea\u884c\u67e5\u9605\u3002<\/span><\/p>\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/span><\/span><\/a><\/p>\n

\u70b9\u51fb\u4e86\u89e3\u66f4\u591a\u8be6\u60c5\uff01<\/strong><\/span><\/p>\n


<\/p>\n

\u8bc6\u522b\u5fae\u4fe1\u4e8c\u7ef4\u7801\uff0c\u6dfb\u52a0\u5c0f\u7f16\uff0c\u7b26\u5408\u6761\u4ef6\u8005\u5373\u53ef\u52a0\u5165\u751f\u7269\u5236\u54c1\u5fae\u4fe1\u7fa4\uff01<\/strong><\/p>\n

\n
\n

\u8bf7\u6ce8\u660e\uff1a\u59d3\u540d+\u7814\u7a76\u65b9\u5411\uff01<\/strong><\/span><\/p>\n

\n
\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/p>\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"
<\/p>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
<\/section>\n
<\/section>\n<\/section>\n
\n
\n
\u7248<\/section>\n<\/section>\n
\n
\u6743<\/section>\n<\/section>\n
\n
\u58f0<\/section>\n<\/section>\n
\n
\u660e<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u672c\u516c\u4f17\u53f7\u6240\u6709\u8f6c\u8f7d\u6587\u7ae0\u7cfb\u51fa\u4e8e\u4f20\u9012\u66f4\u591a\u4fe1\u606f\u4e4b\u76ee\u7684\uff0c\u4e14\u660e\u786e\u6ce8\u660e\u6765\u6e90\u548c\u4f5c\u8005\uff0c\u4e0d\u5e0c\u671b\u88ab\u8f6c\u8f7d\u7684\u5a92\u4f53\u6216\u4e2a\u4eba\u53ef\u4e0e\u6211\u4eec\u8054\u7cfb(cbplib@163.com)\uff0c\u6211\u4eec\u5c06\u7acb\u5373\u8fdb\u884c\u5220\u9664\u5904\u7406\u3002\u6240\u6709\u6587\u7ae0\u4ec5\u4ee3\u8868\u4f5c\u8005\u89c2\u70b9\uff0c\u4e0d\u4ee3\u8868\u672c\u7ad9\u7acb\u573a\u3002<\/span>
<\/p>\n


<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\"\u8fd1\u5341\u5e74\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u91cc\u7a0b\u7891\u5f0f\u4ea7\u54c1\"<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

1. \u201cADP-TCR\u201d\u7597\u6cd5 \u201cADP-TCR\u201d\u7597\u6cd5\u662f\u7531Adaptimmune\u516c\u53f8\u5f00\u53d1\u7684\u4e00\u7cfb\u5217\u5de5\u7a0b\u5316TCR\u9776\u5411 […]<\/p>\n","protected":false},"author":1,"featured_media":107760,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/107759"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=107759"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/107759\/revisions"}],"predecessor-version":[{"id":107772,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/107759\/revisions\/107772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/107760"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=107759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=107759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=107759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}